Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Oveporexton · 1 trial · 1 indication
The MWT evaluates a person's ability to remain awake under soporific conditions for a defined period of time. Because there is no biological measure of wakefulness, wakefulness is measured indirectly by the inability or delayed tendency to fall asleep. This tendency to fall asleep is measured via electroencephalography-derived sleep latency in the MWT. The MWT consists of four 40-minute sessions (trials) done 2 hours apart. Sleep latency in each session was recorded. Participants were required to stay awake in between the four sessions. A positive change from baseline indicates an improvement. The linear mixed effects model for repeated measures (MMRM) was used for analysis.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participants received oveporexton (OVE)-matching placebo tablets, orally, for 12 weeks. |
| OVE 1 mg BID | EXPERIMENTAL | Participants received OVE tablets, 1 milligram (mg), orally, for 12 weeks. |
| OVE 2 mg BID | EXPERIMENTAL | Participants received OVE tablets, 2 mg, orally, for 12 weeks. |
| Name | Type | Description |
|---|---|---|
| Oveporexton | DRUG | Oral tablet. |
| Placebo | DRUG | OVE-matching placebo tablet. |
Inclusion Criteria: 1. The participant has a body mass index (BMI) within the range 18 to 40 kilograms per meter square (kg/m\^2). 2. The participant has an International Classification of Sleep Disorders, Third Edition (ICSD-3) or International Classification of Sleep Disorders, Third Edition, Tex...